SCTX · Scribe Therapeutics, Inc. · Debt
$17.10
+0.90 (+5.56%)
At close · Nov 4
Return incl. dividend (before tax)
Going-concern doubt
— cleared Sep 2, 2026
The latest filing states the doubt was alleviated.
“Substantial doubt about our ability to continue as a going concern existed as of June 30, 2026 and was alleviated as a result of the completion of our initial public offering and concurrent private placement, which resulted in aggregate net proceeds of approximately $140.7 million.”View the 10-Q filed Sep 2, 2026
Market Cap
$320.27M
Shares
18.93M
Volume · Nov 4
204.81K
Avg daily vol (3M)
375.75K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2026-06-30 | USD 1,369,000 | 10-Q filed 2026-09-02 |
| Current portion of convertible notes payable | 2026-06-30 | USD 37,799,000 | 10-Q filed 2026-09-02 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 4,102,000 | 10-Q filed 2026-09-02 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.